[eDisclosure Notice] Samchundang Pharmaceutical Halts Negotiations on 300 Billion KRW Oral Vaccine Investment with Global Pharma (Afternoon Summary)

[Asia Economy Reporter Minji Lee] Samchundang Pharmaceutical announced on the 2nd that it has suspended negotiations after a global pharmaceutical partner informed them that continued development is difficult considering the demand and growth potential of the COVID-19 vaccine market, despite having negotiated a 300 billion KRW investment with global pharmaceutical companies in May last year to develop the world's best oral COVID-19 vaccine.

▲ Megastudy = Announced that the largest shareholder has ultimately decided not to sell shares to MBK Partners.

▲ Melpas = Announced that Cheongun Partners has filed a provisional injunction for suspension of duties at the Suwon District Court Seongnam Branch.

▲ Hanwha = Announced the appointment of Kim Dong-kwan as the new CEO, changing to a multiple CEO system with Geum Chun-soo, Kim Dong-kwan, Ok Kyung-seok, and Kim Seung-mo.

▲ AK Holdings = Announced the decision to issue 130 billion KRW worth of anonymous, unsecured private exchangeable bonds to raise funds for acquiring securities of other companies.